Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JSKN016HC
- Development stage
- Phase 1
- Lead developer
- AlphaMab Oncology
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
JSKN016HC is a subcutaneously injectable formulation of JSKN016, a first-in-class bispecific antibody-drug conjugate (ADC) targeting both HER3 (receptor tyrosine-protein kinase erbB-3) and TROP2. Developed by Jiangsu Alphamab Biopharmaceuticals using a proprietary glycan-specific conjugation platform, JSKN016HC is designed to treat advanced malignant solid tumors. By dual-targeting these two frequently overexpressed tumor antigens, the drug aims to enhance tumor specificity and overcome resistance associated with single-target therapies. The subcutaneous administration of JSKN016HC offers a potentially more convenient delivery method compared to traditional intravenous infusions of ADCs.
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on JSKN016HC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JSKN016HC.